GENETICALLY MODIFIED ONCOLYTIC HERPES SIMPLEX VIRUS DELIVERING CHEMOKINE AND TUMOR-ASSOCIATED/SPECIFIC ANTIGEN Russian patent published in 2024 - IPC A61K35/76 

FIELD: biotechnology.

SUBSTANCE: described is genetically modified oncolytic herpes simplex virus (oHSV), wherein the genome of said oHSV incorporates a polynucleotide encoding (a) a truncated non-signaling variant of at least one tumor-associated/tumor-specific antigen, and (b) at least one chemokine, wherein the expression of said truncated non-signaling variant and said at least one chemokine is under the control of an immediate early HSV gene promoter, and wherein said truncated non-signaling variant is expressed and presented on the surface of the tumor cell as a biomarker during replication of said oHSV in said tumor cell, and said at least one chemokine is expressed and released to induce chemotaxis of the immune cell to said tumor cell. Described is a pharmaceutical kit for treating cancer, comprising, separately, oHSV and a therapeutic agent targeting a tumor, wherein said tumor targeting therapeutic agent has a targeting moiety, specific to said truncated non-signaling variant of at least one tumor-associated/tumor-specific antigen encoded by said polynucleotide, and an effector moiety for providing death or inhibition of cell proliferation of said cancer. Disclosed is a genetically modified oncolytic herpes simplex virus (oHSV), wherein the genome of said oHSV incorporates a polynucleotide encoding a truncated non-signaling variant of at least one tumor-associated/tumor-specific antigen, wherein expression of said truncated non-signaling variant is under control of HSV immediate early gene promoter, and wherein said truncated non-signaling variant is expressed and presented on the surface of the tumor cell as a biomarker during replication of said oHSV in said tumor cell. Disclosed is a pharmaceutical kit for treating cancer, comprising, separately, oHSV and a therapeutic agent targeting a tumor, wherein said tumor targeting therapeutic agent has a targeting moiety, specific to said truncated non-signaling variant of at least one tumor-associated/tumor-specific antigen encoded by said polynucleotide, and an effector moiety for providing death or inhibition of cell proliferation of said cancer.

EFFECT: invention extends the range of products for treating cancer.

29 cl, 19 dwg, 5 tbl